{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:34:27Z","timestamp":1791477267723,"version":"4.3.4"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Steroid-sensitive nephrotic syndrome is a prevalent glomerular disease in children. The 2021 guidelines for glomerular disease management by Kidney Disease: Improving Global Outcomes and the 2023 recommendations for steroid-sensitive nephrotic syndrome management by International Pediatric Nephrology Association recommend rituximab for frequently relapsing nephrotic syndrome and steroid-dependent nephrotic syndrome in children. However, there is considerable variation in rituximab application, including administration timing, dose, frequency, concomitant medications, and follow-up schedules. In addition, rituximab use for nephrotic syndrome remains off-label in most countries.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Data sources<\/jats:title>\n            <jats:p>The \u201cPediatric Nephrology Committee of the Chinese Medical Doctor Association\u201d, the \u201cPediatric Nephrology Society of the Chinese Medical Association\u201d, and the \u201cFudan University GRADE Center\u201d collaborated to develop a clinical practice guideline for rituximab in pediatric steroid-sensitive nephrotic syndrome. Databases and starting\/ending time for retrieval were as follows. Databases in English: PubMed, Embase, Cochrane, and Scopus; database in Chinese: Chinese Biomedical Literature Service provided by SinoMed. The publication dates were limited to those from 2004 to June 26, 2022.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Through systematic reviews and meta-analyses covering nine clinically relevant patient or population covered, intervention, comparator, and outcome questions, seven recommendations were formulated and formally graded according to these guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This guideline aspires to serve as a pivotal resource for healthcare providers, offering guidance on administration timing, dosage, frequency, concomitant medications, and follow-up protocols.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12519-025-00957-9","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T06:52:00Z","timestamp":1755067920000},"page":"775-791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical practice guidelines for rituximab treatment in children with steroid-sensitive nephrotic syndrome"],"prefix":"10.1007","volume":"21","author":[{"given":"Qian","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Kun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei-Lin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Xia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Shan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Shan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7617-0872","authenticated-orcid":false,"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Working Group on Clinical Practice Guidelines for the Rituximab Treatment in Children with Steroid-sensitive Nephrotic Syndrome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"957_CR1","first-page":"282","volume":"61","author":"Nephrology Expert Panel of the Peking University Health Science Center","year":"2022","unstructured":"Nephrology Expert Panel of the Peking University Health Science Center. Expert consensus on the application of rituximab in the treatment of membranous nephropathy. Zhonghua Nei Ke Za Zhi. 2022;61:282\u201390.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"957_CR2","first-page":"151","volume":"61","author":"Chinese Society of Nephrology","year":"2022","unstructured":"Chinese Society of Nephrology. Expert consensus on the use of rituximab in glomerulonephritis. Chin J Nephrol. 2022;61:151\u201360.","journal-title":"Chin J Nephrol"},{"key":"957_CR3","unstructured":"Common Terminology Criteria for Adverse Events v3. 0 CTCAE. 2006. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed 31 March 2003."},{"key":"957_CR4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/clinchem\/28.1.126","volume":"28","author":"CR Jolliff","year":"1982","unstructured":"Jolliff CR, Cost KM, Stivrins PC, Grossman PP, Nolte CR, Franco SM, et al. Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry. Clin Chem. 1982;28:126\u20138.","journal-title":"Clin Chem"},{"key":"957_CR5","first-page":"3167","volume":"45","author":"Chinese Society of Hematology RBCDASG","year":"2022","unstructured":"Chinese Society of Hematology RBCDASG. Chinese expert consensus on the diagnosis and treatment of neutropenia. Natl Med J China. 2022;45:3167\u201373.","journal-title":"Natl Med J China"},{"key":"957_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1081-1206(10)60665-5","volume":"99","author":"S Agarwal","year":"2007","unstructured":"Agarwal S, Cunningham-Rundles C. Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol. 2007;99:281\u20133.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"957_CR7","first-page":"659","volume":"29","author":"J Du","year":"2014","unstructured":"Du J, Huang JP, Wang S, Zhao XY, Xiao LL. The Application of rituximab in children with frequently relapsing nephrotic syndrome. Chin J Appl Clin Pediatr. 2014;29:659\u201362.","journal-title":"Chin J Appl Clin Pediatr"},{"key":"957_CR8","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023;38:877\u2013919.","journal-title":"Pediatr Nephrol"},{"key":"957_CR9","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00467-021-05304-4","volume":"37","author":"Y Inoki","year":"2022","unstructured":"Inoki Y, Kamei K, Nishi K, Sato M, Ogura M, Ishiguro A. Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome. Pediatr Nephrol. 2022;37:1057\u201366.","journal-title":"Pediatr Nephrol"},{"key":"957_CR10","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00467-014-2794-7","volume":"29","author":"YH Ahn","year":"2014","unstructured":"Ahn YH, Kang HG, Lee JM, Choi HJ, Ha IS, Cheong HI. Development of antirituximab antibodies in children with nephrotic syndrome. Pediatr Nephrol. 2014;29:1461\u20134.","journal-title":"Pediatr Nephrol"},{"key":"957_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00467-021-05069-w","volume":"37","author":"Q Bertrand","year":"2022","unstructured":"Bertrand Q, Mignot S, Kwon T, Couderc A, Maisin A, Cambier A, et al. Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2022;37:357\u201365.","journal-title":"Pediatr Nephrol"},{"key":"957_CR12","volume-title":"WHO handbook for guideline development","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. WHO handbook for guideline development. 2nd ed. Geneva: World Health Organization; 2014.","edition":"2"},{"key":"957_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"957_CR14","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:4919.","journal-title":"BMJ"},{"key":"957_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1 introduction\u2014grade evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383\u201394.","journal-title":"J Clin Epidemiol"},{"key":"957_CR16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sch\u00fcnemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380\u20132.","journal-title":"J Clin Epidemiol"},{"key":"957_CR17","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1136\/bmj.i2016","volume":"353","author":"P Alonso-Coello","year":"2016","unstructured":"Alonso-Coello P, Sch\u00fcnemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction. BMJ. 2016;353:2016.","journal-title":"BMJ"},{"key":"957_CR18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273\u201381.","journal-title":"Lancet"},{"key":"957_CR19","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, et al. Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol. 2015;26:2259\u201366.","journal-title":"J Am Soc Nephrol"},{"key":"957_CR20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, et al. Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr. 2018;172:757\u201364.","journal-title":"JAMA Pediatr"},{"key":"957_CR21","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00467-020-04540-4","volume":"35","author":"P Ravani","year":"2020","unstructured":"Ravani P, Lugani F, Pisani I, Bodria M, Piaggio G, Bartolomeo D, et al. Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study. Pediatr Nephrol. 2020;35:1437\u201344.","journal-title":"Pediatr Nephrol"},{"key":"957_CR22","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1007\/s00467-022-05475-8","volume":"37","author":"G Mathew","year":"2022","unstructured":"Mathew G, Sinha A, Ahmed A, Grewal N, Khandelwal P, Hari P, et al. Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial. Pediatr Nephrol. 2022;37:3117\u201326.","journal-title":"Pediatr Nephrol"},{"key":"957_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013157","volume":"97","author":"YH Ahn","year":"2018","unstructured":"Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, et al. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine. 2018;97:e13157.","journal-title":"Medicine"},{"key":"957_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jamapediatrics.2020.6150","volume":"175","author":"P Ravani","year":"2021","unstructured":"Ravani P, Lugani F, Drovandi S, Caridi G, Angeletti A, Ghiggeri GM. Rituximab vs low-dose mycophenolate mofetil in recurrence of steroid-dependent nephrotic syndrome in children and young adults: a randomized clinical trial. JAMA Pediatr. 2021;175:631\u20132.","journal-title":"JAMA Pediatr"},{"key":"957_CR25","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00467-020-04570-y","volume":"35","author":"JA Kari","year":"2020","unstructured":"Kari JA, Alhasan KA, Albanna AS, Safdar OY, Shalaby MA, B\u00f6ckenhauer D, et al. Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2020;35:1445\u201353.","journal-title":"Pediatr Nephrol"},{"key":"957_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00467-011-1997-4","volume":"27","author":"A Sinha","year":"2012","unstructured":"Sinha A, Bagga A, Gulati A, Hari P. Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2012;27:235\u201341.","journal-title":"Pediatr Nephrol"},{"key":"957_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00467-017-3789-y","volume":"33","author":"F Iorember","year":"2018","unstructured":"Iorember F, Aviles D, Kallash M, Bamgbola O. Cost analysis on the use of rituximab and calcineurin inhibitors in children and adolescents with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2018;33:261\u20137.","journal-title":"Pediatr Nephrol"},{"key":"957_CR28","first-page":"161","volume":"13","author":"T Zhang","year":"2018","unstructured":"Zhang T, Shen Q, Xu H, Fang XY, Zhai YH, Gong YN, et al. A self-controlled study on the therapeutic effect and influencing factors of rituximab in the treatment of children with primary refractory nephrotic syndrome. Chin J Evid Based Pediatr. 2018;13:161\u20135.","journal-title":"Chin J Evid Based Pediatr"},{"key":"957_CR29","first-page":"154","volume":"45","author":"M Imran","year":"2021","unstructured":"Imran M, Raza H, Rashid K, Ishaq S, Adnan M. A single center experience of rituximab in treating refractory steroid dependent and steroid resistant childhood nephrotic syndrome. Pak Pediatr J. 2021;45:154\u201360.","journal-title":"Pak Pediatr J"},{"key":"957_CR30","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","volume":"27","author":"MJ Kemper","year":"2012","unstructured":"Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2012;27:1910\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"957_CR31","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10157-016-1328-y","volume":"21","author":"S Fujinaga","year":"2017","unstructured":"Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, et al. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment. Clin Exp Nephrol. 2017;21:671\u20136.","journal-title":"Clin Exp Nephrol"},{"key":"957_CR32","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rav\u00e0 L, et al. B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol. 2016;27:1811\u201322.","journal-title":"J Am Soc Nephrol"},{"key":"957_CR33","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41390-018-0088-7","volume":"84","author":"D Bhatia","year":"2018","unstructured":"Bhatia D, Sinha A, Hari P, Sopory S, Saini S, Puraswani M, et al. Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome. Pediatr Res. 2018;84:520\u20136.","journal-title":"Pediatr Res"},{"key":"957_CR34","first-page":"502","volume":"7","author":"M El Koumi","year":"2013","unstructured":"El Koumi M. Rituximab in steroid-dependent nephrotic syndrome. Iran J Kidney Dis. 2013;7:502\u20136.","journal-title":"Iran J Kidney Dis"},{"key":"957_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00467-018-4052-x","volume":"34","author":"J Hogan","year":"2019","unstructured":"Hogan J, Dossier C, Kwon T, Macher MA, Maisin A, Couderc A, et al. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2019;34:253\u20139.","journal-title":"Pediatr Nephrol"},{"key":"957_CR36","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2013030251","volume":"25","author":"P Ruggenenti","year":"2014","unstructured":"Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Maras\u00e0 M, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25:850\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"957_CR37","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ki.2013.211","volume":"84","author":"P Ravani","year":"2013","unstructured":"Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, et al. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor\u2013dependent idiopathic nephrotic syndrome. Kidney Int. 2013;84:1025\u201333.","journal-title":"Kidney Int"},{"key":"957_CR38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ndt\/gfu267","volume":"30","author":"A Sinha","year":"2015","unstructured":"Sinha A, Bhatia D, Gulati A, Rawat M, Dinda AK, Hari P, et al. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant. 2015;30:96\u2013106.","journal-title":"Nephrol Dial Transplant"},{"key":"957_CR39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00467-015-3245-9","volume":"31","author":"H Webb","year":"2016","unstructured":"Webb H, Jaureguiberry G, Dufek S, Tullus K, Bockenhauer D. Cyclophosphamide and rituximab in frequently relapsing\/steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2016;31:589\u201394.","journal-title":"Pediatr Nephrol"},{"key":"957_CR40","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s00467-017-3718-0","volume":"32","author":"K Kamei","year":"2017","unstructured":"Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, et al. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol. 2017;32:2071\u20138.","journal-title":"Pediatr Nephrol"},{"key":"957_CR41","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.ekir.2023.05.022","volume":"8","author":"B Basu","year":"2023","unstructured":"Basu B, Erdmann S, Sander A, Mahapatra TKS, Meis J, Schaefer F. Long-term efficacy and safety of rituximab versus tacrolimus in children with steroid dependent nephrotic syndrome. Kidney Int Rep. 2023;8:1575\u201384.","journal-title":"Kidney Int Rep"},{"key":"957_CR42","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00467-009-1377-5","volume":"25","author":"S Fujinaga","year":"2010","unstructured":"Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010;25:539\u201344.","journal-title":"Pediatr Nephrol"},{"key":"957_CR43","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6:1308\u201315.","journal-title":"Clin J Am Soc Nephrol"},{"key":"957_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00467-015-3197-0","volume":"31","author":"K Kamei","year":"2016","unstructured":"Kamei K, Ogura M, Sato M, Sako M, Iijima K, Ito S. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab. Pediatr Nephrol. 2016;31:89\u201395.","journal-title":"Pediatr Nephrol"},{"key":"957_CR45","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","volume":"19","author":"K Benz","year":"2004","unstructured":"Benz K, D\u00f6tsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol. 2004;19:794\u20137.","journal-title":"Pediatr Nephrol"},{"key":"957_CR46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","volume":"97","author":"EY Chan","year":"2020","unstructured":"Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL, et al. Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int. 2020;97:393\u2013401.","journal-title":"Kidney Int"},{"key":"957_CR47","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1681\/ASN.2021050643","volume":"33","author":"K Iijima","year":"2022","unstructured":"Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, et al. Mycophenolate mofetil after rituximab for childhood-onset complicated frequently-relapsing or steroid-dependent nephrotic syndrome. J Am Soc Nephrol. 2022;33:401\u201319.","journal-title":"J Am Soc Nephrol"},{"key":"957_CR48","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00467-011-1886-x","volume":"26","author":"S Ito","year":"2011","unstructured":"Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, et al. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011;26:1823\u20138.","journal-title":"Pediatr Nephrol"},{"key":"957_CR49","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00431-012-1913-3","volume":"172","author":"S Fujinaga","year":"2013","unstructured":"Fujinaga S, Someya T, Watanabe T, Ito A, Ohtomo Y, Shimizu T, et al. Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab. Eur J Pediatr. 2013;172:513\u20138.","journal-title":"Eur J Pediatr"},{"key":"957_CR50","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00467-020-04771-5","volume":"36","author":"M Okutsu","year":"2021","unstructured":"Okutsu M, Kamei K, Sato M, Kanamori T, Nishi K, Ishiwa S, et al. Prophylactic rituximab administration in children with complicated nephrotic syndrome. Pediatr Nephrol. 2021;36:611\u20139.","journal-title":"Pediatr Nephrol"},{"key":"957_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/ped.14725","volume":"64","author":"T Takahashi","year":"2022","unstructured":"Takahashi T, Okamoto T, Yokota I, Sato Y, Hayashi A, Ueda Y, et al. The effect of rituximab on the quality of life of children with refractory nephrotic syndrome. Pediatr Int. 2022;64:e14725.","journal-title":"Pediatr Int"},{"key":"957_CR52","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/17843286.2016.1208955","volume":"72","author":"I van Horebeek","year":"2017","unstructured":"van Horebeek I, Knops N, van Dyck M, Levtchenko E, Mekahli D. Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature. Acta Clin Belg. 2017;72:147\u201355.","journal-title":"Acta Clin Belg"},{"key":"957_CR53","first-page":"109","volume":"1","author":"L Wang","year":"2021","unstructured":"Wang L, Hua R, Zhu Y, Lu Y, Gao H, Xia X, et al. Single dose of rituximab in children with steroid-dependent\/frequently relapsing nephrotic syndrome, clinical efficacy and evaluation of health-related quality of life. Iran J Kidney Dis. 2021;1:109\u201315.","journal-title":"Iran J Kidney Dis"},{"key":"957_CR54","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00467-010-1465-6","volume":"25","author":"AL Sellier-Leclerc","year":"2010","unstructured":"Sellier-Leclerc AL, Macher MA, Loirat C, Gu\u00e9rin V, Watier H, Peuchmaur M, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010;25:1109\u201315.","journal-title":"Pediatr Nephrol"},{"key":"957_CR55","first-page":"60","volume":"55","author":"\u0130 Giri\u015fgen","year":"2020","unstructured":"Giri\u015fgen \u0130, Y\u00fcksel S, Pekal Y. Rituximab experience in children with nephrotic syndrome: what have we observed differently. Turk Arch Pediatr. 2020;55:60\u20136.","journal-title":"Turk Arch Pediatr"},{"key":"957_CR56","doi-asserted-by":"publisher","first-page":"257","DOI":"10.23876\/j.krcp.2017.36.3.257","volume":"36","author":"JH Kim","year":"2017","unstructured":"Kim JH, Park E, Hyun HS, Cho MH, Ahn YH, Choi HJ, et al. Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome. Kidney Res Clin Pract. 2017;36:257\u201363.","journal-title":"Kidney Res Clin Pract"},{"key":"957_CR57","first-page":"612","volume":"40","author":"RQ Wang","year":"2021","unstructured":"Wang RQ, Lin DJ, Wu SY, Zhou QH, Chen JS. The effect of rituximab on t lymphocyte subpopulations and urinary CD80 levels in children with steroid-dependent nephrotic syndrome. Dong Nan Da Xue Xue Bao (Medical Edition). 2021;40:612\u20137.","journal-title":"Dong Nan Da Xue Xue Bao (Medical Edition)"},{"key":"957_CR58","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24:1321\u20138.","journal-title":"Pediatr Nephrol"},{"key":"957_CR59","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1681\/ASN.2021111472","volume":"33","author":"EY Chan","year":"2022","unstructured":"Chan EY, Yu ELM, Angeletti A, Arslan Z, Basu B, Boyer O, et al. Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study. J Am Soc Nephrol. 2022;33:1193\u2013207.","journal-title":"J Am Soc Nephrol"},{"key":"957_CR60","first-page":"521","volume":"52","author":"JP Huang","year":"2014","unstructured":"Huang JP, Du J, Wang S, Xiao LL, Zhao XY. Treatment of children with steroid-dependent nephrotic syndrome with rituximab. Chin J Pediatr. 2014;52:521\u20134.","journal-title":"Chin J Pediatr"},{"key":"957_CR61","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1159\/000356439","volume":"38","author":"T Kimata","year":"2013","unstructured":"Kimata T, Hasui M, Kino J, Kitao T, Yamanouchi S, Tsuji S, et al. Novel use of rituximab for steroid-dependent nephrotic syndrome in children. Am J Nephrol. 2013;38:483\u20138.","journal-title":"Am J Nephrol"},{"key":"957_CR62","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00467-012-2406-3","volume":"28","author":"S Tellier","year":"2013","unstructured":"Tellier S, Brochard K, Garnier A, Bandin F, Llanas B, Guigonis V, et al. Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome. Pediatr Nephrol. 2013;28:911\u20138.","journal-title":"Pediatr Nephrol"},{"key":"957_CR63","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00467-014-3034-x","volume":"30","author":"S Fujinaga","year":"2015","unstructured":"Fujinaga S, Sakuraya K, Yamada A, Urushihara Y, Ohtomo Y, Shimizu T. Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2015;30:687\u201391.","journal-title":"Pediatr Nephrol"},{"key":"957_CR64","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/archdischild-2020-319609","volume":"106","author":"C Subun","year":"2021","unstructured":"Subun C, Suwannahitatorn P, Webb H, Tullus K. Rituximab in childhood steroid-sensitive nephrotic syndrome: are multiple subsequent courses safe and effective? Arch Dis Child. 2021;106:815\u20138.","journal-title":"Arch Dis Child"},{"key":"957_CR65","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1681\/ASN.2021040561","volume":"32","author":"P Ravani","year":"2021","unstructured":"Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, et al. Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial. J Am Soc Nephrol. 2021;32:2652\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"957_CR66","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00467-018-4063-7","volume":"34","author":"T Takahashi","year":"2019","unstructured":"Takahashi T, Okamoto T, Sato Y, Yamazaki T, Hayashi A, Aoyagi H, et al. Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study. Pediatr Nephrol. 2019;34:87\u201396.","journal-title":"Pediatr Nephrol"},{"key":"957_CR67","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","volume":"23","author":"V Guigonis","year":"2008","unstructured":"Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008;23:1269\u201379.","journal-title":"Pediatr Nephrol"},{"key":"957_CR68","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.12998\/wjcc.v7.i9.1021","volume":"7","author":"P Marzuillo","year":"2019","unstructured":"Marzuillo P, Guarino S, Esposito T, Di Sessa A, Orsini SI, Capalbo D, et al. Rituximab-induced IgG hypogammaglobulinemia in children with nephrotic syndrome and normal pre-treatment IgG values. World J Clin Cases. 2019;7:1021\u20137.","journal-title":"World J Clin Cases"},{"key":"957_CR69","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00467-019-04398-1","volume":"35","author":"C Parmentier","year":"2020","unstructured":"Parmentier C, Delbet JD, Decramer S, Boyer O, Hogan J, Ulinski T. Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2020;35:455\u201362.","journal-title":"Pediatr Nephrol"},{"key":"957_CR70","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","volume":"25","author":"A Prytu\u0142a","year":"2010","unstructured":"Prytu\u0142a A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010;25:461\u20138.","journal-title":"Pediatr Nephrol"},{"key":"957_CR71","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00467-018-4172-3","volume":"34","author":"AP Maxted","year":"2019","unstructured":"Maxted AP, Dalrymple RA, Chisholm D, McColl J, Tse Y, Christian MT, et al. Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome. Pediatr Nephrol. 2019;34:855\u201363.","journal-title":"Pediatr Nephrol"},{"key":"957_CR72","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00467-020-04629-w","volume":"35","author":"S Fujinaga","year":"2020","unstructured":"Fujinaga S, Nishino T, Endo S, Umeda C, Watanabe Y, Nakagawa M. Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2020;35:2003\u20138.","journal-title":"Pediatr Nephrol"},{"key":"957_CR73","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","volume":"27","author":"AL Sellier-Leclerc","year":"2012","unstructured":"Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Gu\u00e9rin V, Lapillonne H, et al. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood\u2014follow-up after CD19 recovery. Nephrol Dial Transplant. 2012;27:1083\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"957_CR74","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s10157-021-02035-6","volume":"25","author":"M Kobayashi","year":"2021","unstructured":"Kobayashi M, Kageyama Y, Ando T, Sakamoto J, Kimura S. All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome. Clin Exp Nephrol. 2021;25:854\u201364.","journal-title":"Clin Exp Nephrol"},{"key":"957_CR75","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3892\/br.2016.711","volume":"5","author":"XL Niu","year":"2016","unstructured":"Niu XL, Hao S, Wang P, Zhang W, Guo GM, Wu Y, et al. Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome. Biomed Rep. 2016;5:237\u201342.","journal-title":"Biomed Rep"},{"key":"957_CR76","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3389\/fped.2019.00313","volume":"7","author":"R Topalo\u011flu","year":"2019","unstructured":"Topalo\u011flu R, G\u00fclhan B, \u00c7elegen K, \u0130n\u00f6z\u00fc M, Hayran M, D\u00fczova A, et al. Rituximab for children with difficult-to-treat nephrotic syndrome: its effects on disease progression and growth. Front Pediatr. 2019;7:313.","journal-title":"Front Pediatr"},{"key":"957_CR77","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12887-022-03109-4","volume":"22","author":"B Bazargani","year":"2022","unstructured":"Bazargani B, Noparast Z, Khedmat L, Fahimi D, Esfahani ST, Moghtaderi M, et al. Efficacy of rituximab therapy in children with nephrotic syndrome: a 10-year experience from an Iranian pediatric hospital. BMC Pediatr. 2022;22:36.","journal-title":"BMC Pediatr"},{"key":"957_CR78","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000486941","volume":"195","author":"T Takura","year":"2018","unstructured":"Takura T, Takei T, Nitta K. Socioeconomics of administering rituximab for nephrotic syndrome. Contrib Nephrol. 2018;195:110\u20139.","journal-title":"Contrib Nephrol"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-025-00957-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12519-025-00957-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-025-00957-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T01:41:55Z","timestamp":1757382115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12519-025-00957-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":78,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["957"],"URL":"https:\/\/doi.org\/10.1007\/s12519-025-00957-9","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Working Group members and the Evidence-to-Decision (EtD) experts of the RTX Guidelines have all signed the Conflict-of-Interest Declaration. The Working Group consists of nephrologists from the Children\u2019s Hospital of Fudan University and Children\u2019s Hospital of Nanjing Medical University, who voluntarily participated in working group meetings, literature retrieval & screening, evidence extraction, bias risk assessment, and systematic review\/meta-analysis, all for free. The Methodology Team is from Fudan University GRADE Center and volunteers to provide support and training for the methodologies used in the guideline preparation. The EtD meetings were offline, and funded by the research project titled \u201cThe Efficacy and Safety of Rituximab in Reducing Relapse of Steroid-sensitive Nephrotic Syndrome in Children: A Single-Arm, Open-Label, Multicenter Clinical Study\u201d. The review of the manuscripts was by unpaid experts through correspondence. Author Hong Xu, Jian-Hua Mao, and Ai-Hua Zhang are members of the Editorial Board for World Journal of Pediatrics. They were not involved in the peer-review process or the decision to accept this manuscript for publication. The paper was handled by other Editors and has undergone rigorous peer-review process.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No patients participated in this study. However, parents of pediatric nephrotic syndrome patients and social workers, who were adequately informed and equipped with necessary decision support, actively engaged in the Evidence-to-Decision (EtD) meeting for the formulation of recommendations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}